<h4>Background</h4>With the development of thrombopoietin receptor agonists, the prognosis of immune thrombocytopenia (ITP) in patients in whom there was a poor response to first-line treatment has greatly improved. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.